Approved by the FDA in July 1999, Actos (Pioglitazone) is manufactured by Takeda to treat Type 2 diabetes. Actos is in a class of insulin-sensitizing drugs known as thiazolidinediones, and i... Read more
Approved by the FDA in October 2010, Pradaxa (Dabigatran) is marketed by Boehringer Ingelheim Pharmaceuticals, Inc., to reduce the risk of strokes and blood clots in people who have atrial f... Read more
Pharmaceutical giant Merck has agreed to pay up to $36.8 million to settle all lawsuits brought against the company in Canada over its former best-selling painkiller Vioxx. As we all know, M... Read more
In Ciprofloxacin Hydrochloride Antitrust Litigation, the Second Circuit Court of Appeals recently indicated that it is willing to reexamine its prior case law with respect to “reverse settle... Read more
The Swiss pharmaceutical company Novartis AG will pay $72.5 million to settle a whistleblower lawsuit accusing it of improperly billing government programs for unapproved uses of a cystic fi... Read more
The U.S. Department of Justice has reached two settlements with pharmaceutical companies that will call for a total of more than $100 million in penalties under the False Claims Act and the... Read more
Our firm has handled a number of cases involving Stevens Johnson Syndrome (SJS), which is a life-threatening illness. As you may already know, SJS is usually caused by a severe allerg... Read more
The federal government has reached a $520 million settlement with pharmaceutical manufacturer AstraZeneca. The case dealt with the company’s promotion of off-label uses for the antipsy... Read more
Chad Cook is a lawyer in our Mass Torts Section and is currently responsible for a number of cases including Welding Rod litigation, Ortho Evra, Fosamax, Heparin, Digitek and Zithromax litig... Read more
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.